November 24, 2016 - By Linda Rogers · 0 Comments
Lilly Eli & Co (NYSE:LLY) institutional sentiment increased to 1.08 in Q2 2016. Its up 0.01, from 1.07 in 2016Q1. The ratio is better, as 450 hedge funds increased and opened new positions, while 419 cut down and sold their positions in Lilly Eli & Co. The hedge funds in our partner’s database now have: 814.98 million shares, down from 834.25 million shares in 2016Q1. Also, the number of hedge funds holding Lilly Eli & Co in their top 10 positions increased from 22 to 29 for an increase of 7. Sold All: 54 Reduced: 365 Increased: 362 New Position: 88.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $74.43 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 29.53 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
The stock decreased 10.53% or $8 on November 23, hitting $68. About 53.98 million shares traded hands or 1167.14% up from the average. Eli Lilly and Co (NYSE:LLY) has declined 12.63% since April 22, 2016 and is downtrending. It has underperformed by 18.04% the S&P500.
Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on January, 31 before the open. They expect $0.99 EPS, up 26.92% or $0.21 from last year’s $0.78 per share. LLY’s profit will be $1.08B for 17.17 P/E if the $0.99 EPS becomes a reality. After $0.88 actual EPS reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 12.50% EPS growth.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”
Lilly Endowment Inc holds 100% of its portfolio in Eli Lilly and Co for 126.66 million shares. March Altus Capital Management Lp owns 26,810 shares or 16.32% of their US portfolio. Moreover, Sector Gamma As has 14.58% invested in the company for 914,920 shares. The California-based Primecap Management Co Ca has invested 4.82% in the stock. Valueworks Llc, a New York-based fund reported 74,142 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 buy, and 10 sales for $120.57 million net activity.
Ratings analysis reveals 93% of Eli Lilly and Company’s analysts are positive. Out of 15 Wall Street analysts rating Eli Lilly and Company, 14 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $75 while the high is $125. The stock’s average target of $97.88 is 43.94% above today’s ($68) share price. LLY was included in 40 notes of analysts from July 23, 2015. The firm earned “Outperform” rating on Monday, August 24 by Cowen & Co. The rating was maintained by Jefferies on Friday, September 18 with “Buy”. The rating was upgraded by Barclays Capital to “Overweight” on Tuesday, December 1. On Tuesday, August 2 the stock rating was maintained by Argus Research with “Buy”. Leerink Swann maintained the shares of LLY in a report on Thursday, November 12 with “Outperform” rating. The stock of Eli Lilly and Co (NYSE:LLY) has “Buy” rating given on Thursday, August 27 by Berenberg. The stock of Eli Lilly and Co (NYSE:LLY) has “Overweight” rating given on Thursday, September 8 by JP Morgan. Bank of America maintained the shares of LLY in a report on Friday, September 18 with “Buy” rating. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, October 13. The stock has “Outperform” rating given by Credit Suisse on Friday, October 9.
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Marketwatch.com which released: “Eli Lilly shares slide premarket after company says Alzheimer’s drug trial failed” on November 23, 2016, also Forbes.com with their article: “January 2017 Options Now Available For Eli Lilly (LLY)” published on November 23, 2016, Bloomberg.com published: “Eli Lilly’s Diabetes Misery Will Have Company” on October 26, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Fool.com and their article: “Better Buy: Eli Lilly and Co vs. Pfizer” published on October 26, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc” with publication date: November 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers